Radium targets for cyclotron production of .sup.225./sup.Ac in view of targeted alpha therapy

0579004 - ÚJF 2024 RIV US eng A - Abstract
Kellerbauer, A. - Malmbeck, R. - Carrpico De Almeida, C. - Jajcisinova, E. - Eloirdi, R. - Lebeda, Ondřej - Morgenstern, A.
Radium targets for cyclotron production of ²²⁵Ac in view of targeted alpha therapy.
European Journal of Nuclear Medicine and Molecular Imaging. Springer. Roč. 50, Supplement 1 (2023), S11-S11. ISSN 1619-7070. E-ISSN 1619-7089.
[Annual Congress of the European Association of Nuclear Medicine (ENAM'23). 09.09.2023-13.09.2023, Vienna]
Institutional support: RVO:61389005
Keywords : Ac-225 production * radiology imaging * alpha therapy
OECD category: Radiology, nuclear medicine and medical imaging
https://doi.org/10.1007/s00259-023-06333-x

Targeted alpha therapy using the radionuclide Ac-225 has shown remarkable beneft in clinical trials to patients sufering from various cancer types. Currently most Ac-225 is produced from a few sources of Th-229 existing worldwide. However, the total amount available is only sufcient for a few thousand patient doses. Given a projected demand that is several orders of magnitude higher, alternative paths for the production of Ac-225 must be developed. We have been investigating the route
using the Ra-226(p,2n)Ac-225 reaction. It is particularly attractive due to its large cross-section near 17 MeV proton energy and because it can be readily employed at a large number of cyclotron facilities. The excitation function of this reaction has been previously measured by us for a few energies, but discrepancies with calculations remain. Hence, new irradiation experiments are required to improve the knowledge of the excitation function to support the industrial production of Ac-225 via this route.
Permanent Link: https://hdl.handle.net/11104/0347883